Literature DB >> 10854664

Targeted cleavage of HIV-1 coreceptor-CXCR-4 by RNA-cleaving DNA-enzyme: inhibition of coreceptor function.

S Basu1, B Sriram, R Goila, A C Banerjea.   

Abstract

HIV needs the chemokine receptors (HIV-1 coreceptors) to initiate infection and gain entry into a susceptible cell. CCR5 receptor is used by macrophage tropic viruses to establish infection, and CXCR-4 is used by T lymphocyte tropic virus which are usually found at the terminal stages of the disease. These chemokine receptors are, therefore, attractive targets to interfere with the entry as well as spread of HIV-1 in the host. As our antiviral approach, we have earlier assembled a DNA-enzyme-916 against CCR5 (Goila and Banerjea, 1998). We have now designed against the CXCR-4 gene a mono-DNA-enzyme, which showed sequence specific cleavage activity. When CXCR-4-DNA-enzyme was placed in tandem with CCR5-DNA-enzyme, specific cleavage of their respective target sites were observed using a 60 bases long synthetic target RNA which possessed the target sites for both the DNA-enzymes. The cleavage by the CXCR-4 DNA-enzyme was found to be significantly more efficient than by the CCR5-DNA-enzyme. Analyses of the cleaved fragments by mono- and di-DNA-enzyme indicated strongly that hybridization of the CCR5-DNA-enzyme with its cognate target RNA, actually facilitated the cleavage by the CXCR-4 DNA-enzyme. Furthermore, the di-DNA-enzyme was able to cleave the substrate RNA to completion. These DNA-enzymes, when introduced into a mammalian cell line expressing the appropriate chemokine receptor, interfered specifically with the HIV-1 coreceptor functions. Using this strategy, it may be possible to interfere with the infection and spread of R5 as well as X4 viruses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10854664     DOI: 10.1016/s0166-3542(00)00075-9

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  8 in total

1.  In vitro-selected RNA cleaving DNA enzymes from a combinatorial library are potent inhibitors of HIV-1 gene expression.

Authors:  B Sriram; A C Banerjea
Journal:  Biochem J       Date:  2000-12-15       Impact factor: 3.857

Review 2.  The use of cell-delivered gene therapy for the treatment of HIV/AIDS.

Authors:  Geoff P Symonds; Helen A Johnstone; Michelle L Millington; Maureen P Boyd; Bryan P Burke; Louis R Breton
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

3.  DNA computing circuits using libraries of DNAzyme subunits.

Authors:  Johann Elbaz; Oleg Lioubashevski; Fuan Wang; Françoise Remacle; Raphael D Levine; Itamar Willner
Journal:  Nat Nanotechnol       Date:  2010-05-30       Impact factor: 39.213

4.  Inhibition of HIV-1 gene expression by novel macrophage-tropic DNA enzymes targeted to cleave HIV-1 TAT/Rev RNA.

Authors:  H Unwalla; A C Banerjea
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

5.  Mismatch Discrimination and Efficient Photomodulation with Split 10-23 DNAzymes.

Authors:  Brittani K Ruble; Julia L Richards; Jasmina C Cheung-Lau; Ivan J Dmochowski
Journal:  Inorganica Chim Acta       Date:  2012-01-15       Impact factor: 2.545

6.  Solution NMR Spectroscopy as a Tool to Study DNAzyme Structure and Function.

Authors:  Jan Borggräfe; Manuel Etzkorn
Journal:  Methods Mol Biol       Date:  2022

Review 7.  Molecular Features and Metal Ions That Influence 10-23 DNAzyme Activity.

Authors:  Hannah Rosenbach; Julian Victor; Manuel Etzkorn; Gerhard Steger; Detlev Riesner; Ingrid Span
Journal:  Molecules       Date:  2020-07-07       Impact factor: 4.411

8.  Design of efficient DNAzymes against muscle AChR alpha-subunit cRNA in vitro and in HEK 293 cells.

Authors:  Amr Abdelgany; M Khabir Uddin; Matthew Wood; Kazunari Taira; David Beeson
Journal:  J RNAi Gene Silencing       Date:  2005-10-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.